Clinical trial · Interventional
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer
NCT01184287CI-TRIAL-00019010withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Program discontinued
Summary
Brief summary (as posted)
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ranpirnase | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ranpirnase
- description
- All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
- interventionNames
- Drug: Ranpirnase
Primary outcomes (1)
- measure
- Response
- timeFrame
- 4 or more months
- description
- To determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy
Secondary outcomes (2)
- measure
- Progression Free Survival (PFS)
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than 18 years * ECOG less than 2 * Estimated survival of greater than 12 weeks Exclusion Criteria: * Prior systemic chemotherapy for locally advanced or metastatic NSCLC * Use of any investigational agent within 28 days prior to registration * Known hypersensitivity to any of the study drugs * Brain metastases or leptomeningeal disease * History of prior malignancy within the past three years
References
Publications (0)
Data not yet available
No reference posted for this study.